Literature DB >> 10806312

Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer's disease.

L G Sheffield1, J G Marquis, N E Berman.   

Abstract

It has been postulated that microglia contribute to the development of neurofibrillary tangles (NFT) in Alzheimer's disease (AD). We compared the distribution of microglia with that of NFT in both AD and non-AD cases. In AD cases, we found that the extent of area covered by Ricinus communic agglutinin-1 labeled microglia generally paralleled NFT frequency and distribution. Microglia occupied the greatest area in tangle-rich periallocortex/allocortex, a lesser area in association cortex, and the smallest area in tangle-poor primary cortex. Interestingly, this pattern was also present in non-AD cases where there were few to no NFT. These findings suggest that regional variations in microglial distribution may constitute, at least in part, a template for the development of NFT.

Entities:  

Mesh:

Year:  2000        PMID: 10806312     DOI: 10.1016/s0304-3940(00)01037-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  38 in total

1.  Cerebrovascular inflammation is associated with tau pathology in Guam parkinsonism dementia.

Authors:  Petra Majerova; Ralph M Garruto; Andrej Kovac
Journal:  J Neural Transm (Vienna)       Date:  2018-04-26       Impact factor: 3.575

Review 2.  Inflammation and microglia actions in Alzheimer's disease.

Authors:  Colin K Combs
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-11       Impact factor: 4.147

3.  Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees.

Authors:  Melissa K Edler; Chet C Sherwood; Richard S Meindl; Emily L Munger; William D Hopkins; John J Ely; Joseph M Erwin; Daniel P Perl; Elliott J Mufson; Patrick R Hof; Mary Ann Raghanti
Journal:  J Comp Neurol       Date:  2018-11-16       Impact factor: 3.215

4.  Are inflammatory profiles the key to personalized Alzheimer's treatment?

Authors:  Holly M Brothers; Donna M Wilcock
Journal:  Neurodegener Dis Manag       Date:  2013

5.  IFN-γ promotes τ phosphorylation without affecting mature tangles.

Authors:  Andrew Li; Carolina Ceballos-Diaz; Nadia DiNunno; Yona Levites; Pedro E Cruz; Jada Lewis; Todd E Golde; Paramita Chakrabarty
Journal:  FASEB J       Date:  2015-07-08       Impact factor: 5.191

6.  Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Authors:  Thuy-Vi V Nguyen; Lin Shen; Lilith Vander Griend; Lisa N Quach; Nadia P Belichenko; Nay Saw; Tao Yang; Mehrdad Shamloo; Tony Wyss-Coray; Stephen M Massa; Frank M Longo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 7.  Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy.

Authors:  C H Latta; H M Brothers; D M Wilcock
Journal:  Neuroscience       Date:  2014-10-05       Impact factor: 3.590

Review 8.  Therapeutic strategies for tau mediated neurodegeneration.

Authors:  Yasumasa Yoshiyama; Virginia M Y Lee; John Q Trojanowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-20       Impact factor: 10.154

9.  Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Authors:  Kelsey E Melah; Sharon Yuan-Fu Lu; Siobhan M Hoscheidt; Andrew L Alexander; Nagesh Adluru; Daniel J Destiche; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Carey E Gleason; N Maritza Dowling; Lisa C Bratzke; Howard A Rowley; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 10.  Review: microglia in protein aggregation disorders: friend or foe?

Authors:  S M Gentleman
Journal:  Neuropathol Appl Neurobiol       Date:  2013-02       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.